Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Stocks
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
tag
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi（新）
GUSD（纯图）
Rewards

Novartis Acquires Myricx Bio for $1.5B to Secure Next-Gen ADC Payload Technology

GateNews
ABL Bio-7.14%
According to Seoul Economic, Novartis acquired British biotech firm Myricx Bio today for up to $1.5 billion, signaling major pharma's shift toward next-generation antibody-drug conjugates (ADCs). The deal includes an $1.1 billion upfront payment and up to $400 million in milestone payments. Myricx specializes in NMTi (N-myristoyltransferase inhibitor) payload technology for ADCs, representing a novel payload approach beyond current industry standards. Following Daiichi Sankyo and AstraZeneca's success with Enhertu, major pharmaceutical companies are increasingly competing to develop ADCs targeting new antigens and incorporating dual payloads. Korean biotech companies are accelerating similar initiatives: Ligand Chem Biosciences is licensing novel target antibodies, ABL Bio is advancing dual-payload and novel-payload ADC programs, and Genome & Company is developing ADCs targeting CNTN4 and ITGB4 antigens.
View Source
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

Related News

07-19 08:31
SK Hynix ADR Added to 11 Korean ETFs as Nasdaq-Listed Stock Trades at 25% Premium
07-17 22:19
SK Hynix ADR Debuts on Nasdaq, Rises 13.1% on First Day to $168.49
07-17 10:01
Pagebio, Tengrui Pharma, Alibaba Health Sign Strategic Deal on Pardaxin on July 17
07-17 02:16
BlackRock's Korea ETF Sees Record $1.1B Inflow on July 15 as SK Hynix ADR Trades at 27% Premium
07-16 11:49
Eli Lilly Acquires ATAI for $6.75 Per Share, Stock Surges 33% in Pre-Market Trade on July 16
In-Depth Analysis

SK Hynix Stocks Fall 11.53% in Korea as US ADR Closes 12.75% Above Offering

Crypto Frontier07-19 15:15

SK Hynix ADR Surges 8% Following Chairman Choi's Hold Advice

Lucas Bennett07-17 19:24

NBIS Stock Rallies 4% After Nebius Lands $775M Debt Deal for AI Buildout

Crypto Frontier07-17 15:32
Comment
0/400
No comments